The company is entering into 'risk and reward sharing arrangements' with Indian drug makers which are converting from a generic model to one based on R&D.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances